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1. Introduction
Classified as a class one carcinogen, Helicobacter pylori is a gram-negative coccobacillus (0.5
μm wide by 2 - 4 μm long), microaerophilic, flagellated organism that has chronically infected
more than 50% of the world’s population [1, 2, 3, 4]. Significant evidence exist that links the
bacterium to the pathogenesis and development of certain diseases such as gastric ulcers,
chronic gastritis and stomach cancers, although most of the people harboring this organism
are asymptomatic [5, 6]. The prevalence of infection caused by this organism increases with
advancing age and is reported to be higher in developing countries and among low socio-
economic populations, probably owing to conditions that favor the infection such as poor
hygiene, crowded living conditions, and inadequate or no sanitation. The prevalence of this
infection in human varies with geographical location and socio-demographic characteristics
of the population; however does not parallel the incidence of morbidity caused by the infection
[7, 8]. Studies have highlighted inconsistencies in the prevalence rates for Helicobacter and
disease. In industrialized countries there is generally a low prevalence of H. pylori infection
and yet a relatively high prevalence of gastric cancer. On the other hand, some countries with
high Helicobacter prevalence rates have low gastric cancer prevalence [9].
Over the years, different treatment regimens have been proposed for eradication of H. pylori.
Eradication of the organism has proven to be the first therapeutic approach and constitutes a
reliable long-term prophylaxis of peptic ulcer relapse, accelerating ulcer healing and reducing
the rate of ulcer complications [10]. Successful regimens generally require two or more
antibiotics coupled with a proton pump inhibitor [11]. A proton pump inhibitor (PPI) or
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bismuth compounds and two antibiotics most commonly clarithromycin and metronidazole
and/or amoxicillin [12]. However, problems related to poor patient compliance, undesirable
side effect and resistance are presenting with numerous challenges as far as treatment failure
is concern. Antibiotic resistance is a growing global concern both in the developing and in
developed countries. Resistance to this organism has been delineated worldwide [13]. Many
H. pylori strains have been reported to show resistance to the limited range of antibiotics used
in its treatment in vitro. Of particular interest, resistance to metronidazole and clarithromycin
has increased recently with more than 90% resistance reported against metronidazole and up
to 36% against clarithromycin depending on regions [14, 15]. Emerging resistance of the
bacterium to tetracycline, fluoroquinolones, and rifampicins, which are alternative antibiotics
with known anti-H. pylori activity, have also been reported [14].
The emerging resistance to these antibiotics limits their use in the treatment of these infections
[6, 16, 17]. Resistance to the antibiotics commonly used for treatment has been associated with
mutations in specific genes which have been shown to be associated with these antibiotics.
Clarithromycin resistance for example has been associated with point mutations in the
peptidyl transferase-encoding region of 23S rRNA which affects the binding of macrolides to
the bacterial ribosome, while rdxA and frxA are genes whose mutation has been associated
with metronidazole resistance. Other genes such as the P-glycoprotein (P-gp) as well as
mutations of GyrA, GyrB, and 16SrRNA in H. pylori have also been associated with resistance
fluoroquinolone and tetracycline respectively [18, 19].
With the problem of resistance to currently recommended antibiotics; there is the need to seek
alternative compounds from other sources with proven antimicrobial activity to overcome the
problem. This has encourage the search of active agents from natural products, with the
ultimate aim of discovering potentially useful active ingredients that can serve as template for
the synthesis of new antimicrobial drugs [20]. These include medicinal plants, honey and
probiotics which have been variously described to be associated with increase success rates in
the eradication of H. pylori both in vitro and in vivo [21, 22, 23, 24]. Several plants have been
investigated for their anti-H. pylori activity. Some of these plants with proven activity include
Combretum molle, Calophyllum brasiliense, Sclerocarya birrea, Garcinia kola, Alepidea amatymbica,
Bridelia. Micrantha, Peltophorum africanum, Cyrtocarpa procera Kunth and some Strychnos
species [25, 26, 27]. The antimicrobial activity of honey is now well documented [28, 29]. Manyi-
Loh and co-workers investigated the anti-H. pylori activity of three South African honeys; Pure
honey, citrus blossom and gold crest and found that all honey varieties demonstrated varying
levels of anti-H. pylori activity [24]. Evidence exists that probiotics may inhibit growth of H.
pylori, stimulate an immunological response and reduce inflammatory effect of infection by
bacteria increasing the rate of H. pylori eradication [21]. Some probiotics that have been tested
either singly or in combination include Lactobacillus acidophilus, Lactobacillus rhamnosus,
Lactobacillus bulgaricus, Lactobacillus casei, Streptococcus thermophilus, Bifidobacterium infantis and
Bifidobacterium breve [30]. In this communication, we provide information on the prevalence,
epidemiology and antimicrobial chemotherapy and challenges in treatment of H. pylori in an
effort to continuously highlight the clinical and epidemiological significance.
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2. Helicobacter pylori infections, disease and prevalence
Helicobacter pylori (H. pylori) inhabit various areas of the human stomach [17]. The ability of
this organism to convert the stomach acidic environment, a bactericidal barrier with protection
against many infections, makes the environment suitable for its survival [4, 31]. Infection starts
in the gastric antrum and spreads to the corpus, after extensive mucosal damage. Upon
invasion, mucosa damage is caused that is eventually worsened by the acid produced in the
stomach and this may lead to complications (ulcers and cancers) [16, 14]. Half of the world’s
population is infected by this gastric organism [32]. Since its discovery in 1983 by Marshall
and Warren, infection with H. pylori has been shown to be strongly associated with chronic
gastritis, peptic ulcer and gastric cancer using technologies available at the time and others
(fibre endoscopy, silver staining of histological sections and culture techniques for microaer‐
ophilic bacteria). These authors proved beyond reasonable doubts that made an indisputable
link between the bacteria and the diseases mentioned [3, 33].
Confirmed is the fact that this organism causes of 90% of all duodenal ulcers, 75% of all gastric
ulcers and two forms of stomach cancer; adenocarcinoma and mucosa-associated lymphoid
tissue (MALT) lymphoma [34]. The evidence of its association with gastric cancer, led to its
classification as a class 1 carcinogen by the International Agency for Research on Cancer and
the World Health Organization [35]. H. pylori is the first bacterium, and the second infectious
organism after hepatitis B virus to be classified a carcinogen. A majority of H. pylori-infected
individuals of (80–90%) have clinically asymptomatic gastritis, 10–15% develop peptic ulcer,
and 1–2% gastric malignancies [36, 37]. Until the discovery of Marshall and Warren, diet, stress
and life-style factors were considered major causes of gastritis and peptic ulcer, and the
stomach, a sterile environment [38, 39].
Clinical outcome of long-term infection is variable and is considered to relate to bacterial
virulence factors along with host genotype, physiology and environmental factors [40, 41, 42,
43]. The cytotoxin-associated gene, cagA, a marker for the cag pathogenicity island (PAI), is
present in many but not all H. pylori strains. Its presence is associated with more severe clinical
outcomes [44, 45]. H. pylori infection confers around a two-fold increase in the risk of devel‐
oping gastric cancer particularly with strains expressing the cytotoxin-associated gene A
antigen (cagA) [46]. The vacA gene is far from the cag PAI. At least some forms of vacA protein
generate vacuoles in epithelial cells, disrupt tight junctions between epithelial tissues, interfere
with antigen processing, etc. [47]. The vacA gene is present in all H. pylori strains and contains
two importantly variable regions, s and m [40].
Geographic differences in predominant H. pylori genotypes, based either on virulence associ‐
ated genes such as vacA and cagA or “housekeeping genes” have been delineated [40, 48].
Several other H. pylori genes that are related to the risk of disease have been identified some
of which include, iceA and several other housekeeping genes” such as ureA, ureC, ureAB, flaA,
flaB, atpA, efp, mutY, ppa, trpC, ureI, yphC etc, which may not be directly linked to disease [49,
50]. The cytotoxin-associated gene, cagA, a marker for the cag pathogenicity island (PAI), is
present in many but not all H. pylori strains. Its presence is associated with more severe clinical
outcomes [44, 45].
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H. pylori is the principal species of the genus Helicobacter and a common human pathogen that
is responsible for a variety of gastro–duodenal pathologies with high prevalence reported both
in the developed and developing world since its discovery in 1983 by Marshall and Warren
[51, 52]. Different studies worldwide have demonstrated the presence of this organism in their
population. Substantial morbidity and mortality have been reported to be associated with H.
pylori infection [15, 17, 42]. Fallen prevalence values has been observed in most developed
countries; with rates from 25–50% in developed countries to 70–90% in the second and third
world countries, this however varies [2, 7, 16, 53]. With improvements in treatments modalities,
gastrointestinal pathology related to H. pylori is still ever present and remains a major burden
on Western health systems. Populations like African American, Hispanic, Asian and Native
American have experienced increased prevalence and infection rates are similar in males and
females [54].
Rate of acquisition, rate of loss of infection and the length of persistence period all seem to
determine the prevalence of this highly inflicting pathogen [7]. The prevalence of H. pylori
infection has also been reported to vary widely by geographic area, age, socioeconomic status
and even between ethnic groups of the same region [8, 15]. All these factors including envi‐
ronmental factors all play a role in the acquisition and transmission of H. pylori and further
influence the wide variation in prevalence observed in the different population [55]. For
example, variation exist the prevalence between more affluent urban populations and rural
population. A lack of proper sensitization, drinking water and basic hygiene as well as poor
diet and overcrowding all play a role in determining the overall prevalence of infection [2].
Although there is geographical and socio–demographic variation in the prevalence of human
infection, prevalence does not parallel the incidence of morbidity caused by the infection [2,
16, 56]. Astoundingly high prevalence of H. pylori infection is observed in developing countries
which does not commensurate the low prevalence of gastric cancer compared to the developed
nations with a relatively low prevalence and yet a high prevalence of gastric cancer. For
example, in Africa, the prevalence of infection is very high but the incidence of gastric
carcinoma and other H. pylori-associated morbidities is relatively low. An anomality termed
the African enigma’ [6, 42]. Apparently, coinfection with other organisms is known to
modulate the H. pylori immune reaction and has been proposed to explain the “African
enigma” [57]. The organism is ubiquitous with childhood acquisition seemingly being the role
and may last for years or decades however, it is difficult to ascertain when infection occurs
clinically hence seroprevalence data are the source of information of H. pylori rates both in
geographically and demographically diverse populations [2, 52, 58, 59, 60]. Retrospective sero-
epidemiological studies have shown a cohort effect consistent with the hypothesis that
infection is mainly acquired in early childhood [59, 61]. Seroprevalence values of (61%–100%)
have been described from various studies conducted in Africa and these values vary among
countries and between different racial groups present within each country [2, 42, 53]. Sero‐
prevalence studies in the western world have depicted rates not as high as those elaborated in
Africa. Most individuals harbour specific antibodies for most of their lives especially in Africa
[42].
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In a rural village of Linqu Country, Shandong Province, China, a study of 98 children found
that nearly 70 percent of those aged 5-6 years were infected with H. pylori, a rate equivalent to
that reported for adults in that area, suggesting that most infection takes place early in
childhood [61]. Generally, 50% of all children are infected by the age of 10 years, with preva‐
lence rising to 80% in adults [7]. In their study of Kenyan school children, Nabwera and co-
workers observed high prevalence among their subjects who were only aged 3–5 years,
indicating that most children in the study area were infected before they reached their third
birthday [62]. The highest rates of H. pylori prevalence have been reported in Eastern Europe,
Asia, and many developing countries and developing populations in developed countries (for
example, Native Americans) [63].
3. Repository of infection and transmission
Accurately assessing the incidence or route of transmission of H. pylori has been difficult
because of the inaccuracy and cost of detecting (non-invasively) H. pylori [59]. Studies with
regards to environmental factors and animal reservoirs as possible sources of infection have
been examined. DNA has been extracted from food, animals and water sources suggesting
they could be reservoirs of this organism [37]. However, there is no definitive evidence that
they are natural or primary vehicles of transmission. Various studies have remarked a variety
of factors such as bacterial host, genetic and environmental factors to determine the causative
links to H. pylori infection, but knowledge of reservoirs and transmission still remains elusive
[61]. Some routes of transmission have been described this include iatrogenic, oral-oral or
faecal-oral routes [64, 65].
The host range of H. pylori is narrow and is found almost exclusively in humans and some non-
human primates [66]. Humans been the only known reservoir of infection, hence the possibility
of picking the infection from siblings, parents predominates via gastro-oral route [67]. Using
specific culture approaches the organism has been isolated from vomitus [68, 69]. Perhaps the
most important transmission route is faecal-oral transmission. Typically, isolation of this
organism from faeces is not common though its isolation from faeces is established [61]. Sexual
transmission of these organisms has not been observed [70].
Oral-oral transmission is regarded as a plausible route [39]. It has been shown to be potentiated
by specific eating habits, such as the premastication of food by mothers before feeding children
in some African countries. In Burkina Faso, premastication of food was common amongst
families with high sero-positivity H. pylori status for both mother and child [71]. The impor‐
tance of this cannot be over emphasized considering that childhood appears to be the critical
period during which H. pylori is acquired, especially in areas of over-crowding and socio-
economic deprivation [3, 24]. Possibility of dental plaque been a route of transmission has been
proposed but this has failed in other studies though [72, 73]. In a recent study in South Africa,
it was deduced that the oral cavity is unlikely to contribute to the spread of this organism as
oral cavities were found not to favour prolonged colonization by the organism [53, 74].
Repeated use of gastric tubes from one patient to another by enodoscopists without proper
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sterilization may be a possible means of transmission. H. pylori infection has been shown to
follow socio- other studies [73]. Gastroenterologists are occupationally at risk, however has
proven the least common form of transmission [75].
4. Helicobacter pylori treatment
The need for an adequate prophylactic or therapeutic measures for H. pylori is very important
being a serious, chronic, progressive and transmissible infection associated with significant
morbidity and mortality especially in the developing world [76]. Over the years, several
treatment regimens have been proposed for the eradication of H. pylori. However, develop‐
ment of a successful treatment for H. pylori infection has been fraught with difficulties; owing
to its location within the stomach (that is, the mucus lining the surface epithelium, deep within
the mucus secreting glands of the antrum, attached to cells and even within the cells) providing
a great challenge to therapeutic measures [77]. The hostile environment in the gastric mucosa
poses additional challenges reasons being the antibiotic therapy need to be active at pH values
below neutral [24]. In addition, the ever existing presence of emerging resistant strains presents
a formidable challenge which is at the verge of frustrating every attempt to a solution provision
[78]. Infection with H. pylori will persist for life and may result in severe gastro duodenal
complications without the intervention of antimicrobial therapy (treatment) [52, 79]. Complete
eradication of the organism from the gut or stomach is the ultimate goal to treatment. A
negative test for the bacterium four weeks or longer after treatment defines eradication [80].
There has been evolution with regards to treatment regimen for H. pylori infection since the
early 1990s, when monotherapy was first recommended. However, employment of single
agent is unacceptable because of extremely low eradication rates. H. pylori infections are treated
with antibiotics, H2 blockers which reduces stomach acidicity and a proton pump inhibitor
(PPI) that protects the stomach lining (bismuth compounds). This triple drug regimen
involving; two antibiotics, bismuth salt and a proton pump inhibitor (PPI) or H2 blockers has
been used as a standard treatment [13, 77, 81]. Bismuth compounds (colloidal bismuth sub
citrate and bismuth subsalicylate) act by reducing intracellular ATP levels and interfere with
the activity of urease enzyme, a key enzyme of H. pylori [77]. They also induce the formation
of an ulcer-specific coagulum, preventing acid back diffusion and inhibit protein and cell wall
synthesis as well as membrane function [82, 83]. Detachment of H. pylori from the gastric
epithelium and a reduction in capsular polysaccharide production is the enabling function of
bismuth compounds [77]. Typically, two types of acid reducers exist and include a proton
pump inhibitor (PPI) and H2 blockers. H2 blockers include cimetidine, ranitidine, famotidine
and nizatidine and this function by blocking histamine, which stimulates acid secretion. The
PPI (omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole) on its part
suppresses acid production by halting the mechanism that pumps the acid into the stomach
[84]. PPI also increases antibiotic stability and efficacy [85].
The most commonly used antibiotics include metronidazole (MET), clarithromycin (CLR),
amoxicillin (AMOX) and tetracycline (TET) all of which H. pylori is susceptible too except in
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cases of drug resistance [13, 86, 87]. Clarithromycin (500 mg twice a day [b.i.d.]) and amoxicillin
(1 g b.i.d.) plus PPI for 7 days (treatment 1) are the most commonly used treatment combination
the world over. Other regimens employed for 7-day include clarithromycin (500 mg b.i.d.) and
metronidazole (500 mg b.i.d.) (treatment 2) and a double dose of PPI plus or amoxicillin (1 g
b.i.d.) and metronidazole (500 mg b.i.d.) (treatment 3) a double dose of PPI plus [88]. Efficacy
of the agents range from 85% - 95%. Susceptibility of H. pylori to these drugs has been reported
to change with time, ethnicity, ulcer status, geographical location and test method [14].
Consequently, antibiotic recommended for patients may soon differ across regions of the
world because different areas have begun to show resistance to particular antibiotics. These
factors therefore have to be considered in making a prescription for the eradication of the
infection.
5. Challenges to Helibacter pylori treatment regimens
The recommended regimens for H. pylori treatment and eradication pose a number of diffi‐
culties to patients such as poor compliance; coping with unpleasant adverse effects do little to
encourage patient cooperation [15, 78]. Apart from patient non-compliance, antibiotic resist‐
ance is the major cause of treatment failure leaving clinicians with a limited list of drugs to
choose from [14, 15, 89]. This can seriously affect attempts to eradicate the bacterium. Bacterial
resistance to antimicrobials could be either primary (that is, present before therapy) or
secondary (that is, develop as the result of failed therapy [77]. In different countries primary
resistance in H. pylori has been reported in MET (6-95%), CLR (0-17%), and TET (0-6%) [90,
91]. Fairly recently, resistance to amoxicillin has been reported in many countries across the
globe especially countries in Africa like Cameroon, Nigeria and South Africa where stringent
control of drugs is lacking [17]. On the other hand metronidazole-containing regimens have
recently been shown to have limited effectiveness owing to the alarming increase in the
prevalence of resistance to this drug. Resistance to this antibiotic varies from 10% to 90% in
different countries [92]. For example, Studies by Boyanova and colleagues reported a resistance
rate of 28.6% for metronidazole against clinical isolates of H. pylori circulating in Sofia, Bulgaria
[17, 90]. In our study in South Africa we reported a rate of 95.5% resistant. In Cameroon, studies
have documented a very high resistance to metronidazole. Studies in Australia showed a
resistance level of 36% of H. pylori isolates against metronidazole [93]. High resistance to
metronidazole is attributed to the frequent and uncontrolled use of nitroimidazole derivatives
for the treatment of protozoan infections and gynecological problems [17]. Clarithromycin
resistance is referred to as the corner stone for treatment failure and is increasing worldwide
[94]. A prevalence rate of 12.9% was recorded for Clarithromycin resistance in the U.S and
rates as high as 24% were some European countries [91]. Resistance to clarithromycin fre‐
quently develops after treatment failure and more recently due to its increasing use in the
treatment of upper respiratory tract infection [92]. Increasing prevalence of resistance to
antimicrobial jeopardizes the success of therapeutic regimens aimed at the eradication of the
infection making it sensitivity testing imperative prior to appropriate antibiotic selection [95].
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Also, current antimicrobial susceptibility profiles of the isolates within the region should be
known as this will act as a guide to clinician [96].
Resistance mechanisms to the commonly used antibiotics have been elaborated. Selection
pressure may progressively increase resistance with the use of these antibiotics [88]. Plasmid
associated resistance is rare. Drug efflux proteins can contribute to natural insensitivity to
antibiotics and to emerging antibiotic resistance as is the case of many bacteria [97].
5.1. Metronidazole resistance mechanisms
Resistance to metronidazole (Mtz) has shown to limit the effectiveness of Mtz containing
regimens [98, 99]. Mtz, a synthetic nitroimidazole is a prodrug and becomes active when
reduced in the cytosol of the microorganism to a toxic metabolite. Unstable Mtz radicals react
rapidly with proteins, RNA and DNA, eventually resulting in cell death [88, 99, 100]. Most Mtz
sensitivity in H. pylori accounted for by NADPH nitroreductase a non-oxygen sensitive
encoded by the rdxA gene reduces Mtz by a two-electron transfer step into a toxic metabolite
that cannot be retransformed to its parent by molecular oxygen [99]. Resistance to Mtz is
associated with mutation somewhere in the rdxA coding sequence [101]. Mutation of a second
reductase NAD (P) H flavin oxidoreductase encoded by frxA could also confer low-level Mtz
sensitivity in some strains [102]. Such resistance has been linked mostly to genetic mutations
in the rdxA and frxA genes of the bacterium [100]. Based on gene sequencing and other reports
concluded that most Mtz resistance in H. pylori depend on rdxA inactivation, of which
mutations in frxA can enhance resistance, and that genes conferring Mtz resistance without
rdxA inactivation are rare or nonexistent in H. pylori populations [100].
5.2. Resistance mechanisms to clarithromycin
Clarithromycin is part of the combination therapy used as the first-line therapy against H.
pylori. Resistance to clarithromycin therefore is important ingredient for treatment failure.
Clarithromycin acts by binding to the peptidyl transferase region of 23SrRNA and inhibits
bacterial protein synthesis just like other macrolides Clarithromycin resistance has been linked
to mutation in the 23S rRNA gene [103]. Several reports have demonstrated that more than
90% of macrolide resistance in H. pylori is mediated by either of two transition mutations
Adenine to Guanine (A→G) at adjacent positions 2142 and 2143 in the bacterium’s 23SrRNA
gene [103]. A transversion mutation (A→C) at position 2143 has been reported to be the cause
of resistance in 7% of the resistant isolates. Other mutation observed in clarithromycin resistant
H. pylori isolates include A2515G and T2717C, A2116G, G2141A, A2144T, T2182C, G2224A,
C2245T
5.3. Amoxicillin resistance mechanisms
H. pylori resistance to amoxicillin is not common. Deloney and schiller, showed that amoxicillin
resistance in H. pylori could develop because of amino acid substitutions in the penicillin
binding proteins (pbp) leading to structural alterations in the protein or interference with
peptidoglycan synthesis [104]. Resistance to amoxicillin and related drugs is usually as a result
Trends in Helicobacter pylori Infection250
of decreased permeability to the drug; increased efflux of the drug from the bacterial cell,
modification of the PBPs that diminish the affinity of the drug for the protein, and the presence
of β-lactamases that inactivate the antibiotic by hydrolyzing its ring structure [105]. Amoxi‐
cillin-resistant H. pylori strains harbour mutations on the pbp-1a gene with amino acid
substitution Ser-414→Arg appears to be involved, leading to a blockage of penicillin transport.
Resistance to amoxicillin may also result from the production of β -lactamases by the bacterium
[106]. Colonization of the stomach with β -lactam- resistant bacteria of other species may lead
to the transfer of amoxicillin resistance to H. pylori [17]. Mutations in hopB and hopC genes of
the outer membrane have also been associated with resistance in amoxicillin [107].
5.4. Tetracycline resistance mechanism
Tetracyclines are often used as a second line therapy when H. pylori infections are not cured
by the first line drug regimen. Tetracycline is a protein synthesis inhibitor. This is achieved by
disrupting codon-anticodon interaction on the ribosome. It binds to the 30S ribosomal subunit,
preventing attachment of aminoacyl-tRNA to the acceptor site [108]. Thus bacterial peptide
synthesis is stopped leading to cell death. Resistance to tetracycline has been linked to mutation
in 16SrRNA-encoding genes that affect the binding site of tetracycline. The change in a
nucleotide triplet (AGA-926 to 928→TTC), cognate of the positions 965 to 967 in Escherichia
coli, has been associated with resistance to these compounds maybe because of the absence of
the h1 loop; the binding site of tetracyclines. Strains resistant to tetracycline and no mutation
in position 926 to 928 have also been described [14, 86, 109].
5.5. Resistant Mechanism to Fluoroquinolone
Fluoroquinolones have proven their worth in the treatment of most infections. In the man‐
agement of H. pylori infection, they are used as salvage therapy when all other therapies cannot
help (Chisholm and Owen, 2009). Their mode of action is based on inhibition of A and B
subunits of the gene encoding DNA gyrase (gyrA or gyrB) in the bacterial cell [110], automat‐
ically interfering with DNA replication. Resistance to quinolones is associated mutations in
gyrA at positions 87 and 91 [105, 111].
5.6. Resistance associated to plasmid and Efflux mechanisms
Approximately half of H. pylori strains possess a plasmid with size ranging 1.8-63 kbp though
the standard strain NCTC 11637 is plasmid free [112]. Plasmid size and number may vary
appreciably amongst strains with a gross majority of strains possessing just one plasmid. H.
pylori plasmids have also been associated with drug resistance though in their study indicated
resistance was unlikely to be attributed to plasmid coded determinants [52, 113]. Drug efflux
mechanism could be responsible for the observed resistance in H. pylori as well. Organisms
get protected from possible toxic effects of metabolite accumulation or external compounds
using the efflux mechanism. Compound efflux which is mediated through specific pumps
could result in decreased susceptibility for a variety of antibiotic [114, 115]. Some families of
multidrug efflux transporters have been described these include small multidrug resistance
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(SMR) proteins, multidrug and toxic compound extrusion (MATE) proteins, the major
facilitator superfamily (MFS), the ATP-binding cassette (ABC) superfamilies, and the resist‐
ance-nodulation-cell division (RND) family (helfF, hefC, and hefI) [116]. These active multi‐
drug efflux mechanism and therefore compound efflux needs to be taken into account when
determining resistance mechanisms in this organism. The therapy used for salvage of H.
pylori has as one of its medications rifampicin and rifabutin [105]. Due to their irreversible
blockage of DNA-dependent RNA polymerase; they are bactericidal. The β-subunit of the
polymerase encoded by rpoB gene is inhibited by these medications and annuls protein
synthesis of the bacteria [35, 117]. Resistance of H. pylori to these medications has been
attributed to point mutations in the rpoB gene at positions 530, 540 and 545 [118].
6. Substitutes to circumvent challenges to treatment regimens
Due to the shortcoming presented by antibiotics with regards to treatment of H. pylori; Research
towards development of new antimicrobial agents/ in a bid to scavenge for possible alterna‐
tives to overcome the problem of antibiotic resistance in this bacterial pathogen has been
encouraged, such as research with plant extract and other natural products that possess
antimicrobial potential like honey and probiotics with or without antibiotic both in-vitro and
in-vivo to test for the antimicrobial activity [22, 24, 29, 119, 120].
6.1. Plants as a potential source of H. pylori treatment
Plant and plant products have repeated shown awesome hope in the treatment of recalcitrant
infection. Medicinal plants usage all over the world preface the introduction of antibiotics and
other modern drugs. It is estimated that plant materials are present in or have provided the
models for about 50% of Western drugs [121]. Herbal medicines remain a normal part of life
for most people worldwide especially amongst Africans and Asians and remains a component
of healthcare in most countries worldwide especially Africa [121, 122]. WHO (World Health
Organization) estimates 3.5 million people in developing countries rely on plant-based
medicine for their primary healthcare and their usage has offered great benefit [122, 123, 124].
Research on herbal product has great significance for plants components could provide lead
products for the development of new drugs hence leading to improvement of therapeutic
results [124].
The demand to use natural products such as plants based products for the management of
intractable infections has increased over the years [22]. Great attention has been directed to the
screening of medicinal plants all over the world as a means to identify cheap sources of new
drugs against H. pylori, a human gastric pathogen with high morbidity rate [2]. Scientific
literature is rich on plant based studies on anti-H. pylori activity. A number of plants belonging
to various families as well as compounds have been screened in the search for their anti-H.
pylori potential worldwide. For example, Garlic (Allium sativum L) particularly allium vegeta‐
bles have been shown exhibit a broad range of antibiotic spectrum against both Gram–positive
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and Gram negative bacteria including susceptibility to H. pylori antibiotic resistant strains
[125]. Zeyrek and Oguz demonstrated in vitro anti-H. pylori activity of capsaicin at a concen‐
tration of 50μg/ml against metronidazole resistant and metronidazole-susceptible clinical
isolates [126]. This plant also known as hot pepper is consumed as a flavoring spice and is
reputed for its pharmacological, physiological and antimicrobial effects [127]. There is lower
ulcer prevalence in people consuming higher amount of pepper compared to controls [128].
Studies by Zhang and colleagues in the Linqu County of Shandong Province, China, suggested
that dietary consumption of cranberry (Vaccitnium macrocarpon) juice may reduce H. pylori
infections in adults, which remains an important public health issue worldwide [129]. More
plants which have been tested and proven to exhibit anti- H. pylori activity from their different
continents in the world are listed (Table 1).
Analysis of tested plant extract revealed the presence of varying numbers of components
depending on different solvent combination used for extraction. For example, 52 compounds
were identified from acetone extract of S. birrea (which has been reported with anti- H. pylori
activity) with n-octacosane being the most abundant (41.68%). Other compounds such as
pyrrolidine, terpinen-4-ol, n-eicosane, cyclopentane, n-triacontane, aromadendrene and α-
gujunene were delineated in S. birrea. Terpinen-4-ol and pyrrolidine however demonstrated
strong antimicrobial activity against H. pylori at all concentrations tested. The identified
compounds Terpinen-4-ol could be considered for further evaluation as therapeutic or
prophylactic agents in the treatment of H. pylori-related infections [130]. Other compounds
including quinones, flavones, flavonoid, flavonols, tannins, coumarins, traces of alkaloid,
gallotannins, steroids (including β-sitosterol), phenolics and polyphenols, Terpenoids and
essential oils Alkaloids, lectins and polypeptides have been isolated from most plants and
found to exhibit profound antimicrobial activities in-vitro against an array of organisms
although most of these compounds have not been tested against H. pylori [131].
The stem bark of the South American trumpet tree (Tecoma ipe Mart) has been reported as an
important source of active quinone compound against H. pylori furanonaphthoquinone was
isolated from this plant and has proven activity against H. pylori with (MIC 0.1μg/mL).
idebenone, duroquinone, menadione, juglone and coenzyme Q1 are other quinines that have
been reported with anti- H. pylori at low concentration of 0.8 to 3.2 μg /mL [132]. Anti-H. pylori
activity of a number of flavonoids has been reported. In Turkey for example, Cistus laurifo‐
lius flower buds which is used traditionally in folk medicine to treat gastric ailments have been
shown to possess significant anti-H. pylori activity with the flavonoid; quercetin 3-methyl ether
(isorhamnetin) as the active component [133]. Inhibition of urease is recorded as the mecha‐
nism of action of some flavonoids as hesperidin [134]. Antimicrobial activity of coumarins
isolated from the roots of Ferulago campestris against H. pylori isolates in Italy [135]. Kawase
and others, found that a number of hydroxycoumarins;7- hydroxy-4-methylcoumarin, 6, 7-
dihydroxy-4-methylcoumarin, 6-hydroxy-7-methoxy-4-methylcoumarin and 5, 7- dihydrox‐
ycyclopentanocoumarin showed comparable anti-H. pylori activity with metronidazole [136].
Generally, data about specific antibiotic properties of coumarins against H. pylori are scarce.
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Continent and Species Parts Used Reference
Africa Country
Combretum molle (Combretaceae) South Africa Stem bark [172]
Bridelia micrantha (Hochst, Baill., Euphorbiaceae). South Africa Stem bark [173]
Lippia javanica South Africa Leaves [174]
Hydonora africana South Africa check [175]
Sclerocarya birrea (Anacardiaceae) South Africa Stem bark [130]
Garcinia kola Heckel (Guttiferae) South Africa Seeds [176]
Peltophorum africanum (Sond, Fabaceae) South Africa Stem bark [23]
Ageratum conyzoides (Linn) Cameroon Whole plant [176]
Lycopodium cernuum (Linn) Pic. Serm Cameroon check [17]
Enantia chlorantha Oliver (Annonaceae) Cameroon Stem bark [177] [178]
Eucalyptus camaldulensis Dehnh. Nigeria Leaves [179]
Eucalyptus torelliana F. Muell. (Myrtaceae), Nigeria Stem bark [179]
Europe
South America/ North America
Byrsonima intermedia A. Juss. (Malpighiaceae) Brazil Leaves [180]
Croton cajucara Benth. (Euphorbiaceae) Brazil Stem bark [181]
Piper carpunya Ruiz & Pav. (syn Piper lenticellosum
C.D.C.) (Piperaceae) Ecuador Leaves [182]
Calophyllum brasiliense (Camb.) Brazil Stem bark [25]
Artemisia douglasiana Besser (Asteraceae) Argentina Leaves [183]
Alchornea triplinervia Brazil Leaves [184]
Hancornia speciosa Gomez (Apocynaceae). Brazil Bark [185]
Olea europaea L. (Oleaceae) Mexico Leaves/stem [186]
Tagetes lucida Cav. (Asteraceae) Mexico Leaf/stem [186]
Amphipterygium adstringens (Schltdl.) Standl.
(Anacardiaceae) Mexico Bark [186]
Priva grandiflora (Ortega) Moldenke (Verbenaceae) Mexico Aerial parts [186]
Eupatorium petiolare Moc. ex DC. (Asteraceae) Mexico Aerial parts [186]
Monarda austromontana Epling (Lamiaceae) Mexico Aerial parts [186]
Gnaphalium canescens DC. (Asteraceae) Mexico Aerial parts [186]
Larrea tridentata (Sessé & Moc. ex DC.) Coville
(Zygophyllaceae) Mexico Aerial parts [186]
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Continent and Species Parts Used Reference
Tithonia diversifolia (Hemsl.) A.G. Asteraceae) Mexico Aerial parts [186]
Grindelia inuloides Willd. (Asteraceae) Mexico Aerial parts [186]
Buddleja perfoliata Kunth (Loganiaceae) Mexico Aerial parts [186]
Heterotheca inuloides Cass. (Asteraceae) Mexico Aerial parts [186]
Mirabilis jalapa L. (Nyctaginaceae) Mexico Aerial parts [186]
Cyrtocarpa procera Kunth (Anacardiaceae) Mexico Bark [186]
Teloxys graveolens (Willd.)W.A.Weber
(Chenopodiaceae) Mexico Aerial parts [186]
Annona cherimola Mill. (Annonaceae) Mexico Leaf/stem [186]
Mentha×piperita L. (Lamiaceae) Mexico Leaf/stem [186]
Cuphea aequipetala Cav. (Lythraceae) Mexico Aerial parts [186]
Ludwigia repens J. R. Forst. (Onagraceae) Mexico Aerial parts [186]
Artemisia ludoviciana Nutt. subsp. mexicana (Willd. Ex
Spreng.) Fernald (Asteraceae) Mexico Leaf/stem [186]
Qualea parviflora Mart. Brazil bark [187]
Calophyllum brasiliense Brazil stem bark [25]
North America
Cyrtocarpa procera Kunth (Anacardiaceae) Mexico Bark [27]
Amphipterygium adstringens (Schltdl.) Standl.
(Anacardiaceae) Mexico Bark [186]
Casimiroa tetrameria Leaves [188]
ASIA
Wasabia japonica Japan Leaves [189]
Impatiens balsamina L Asia Root/stem/leaf, seed,and pod [190]
Rhizopus oligosporus Asia fenugreek extracts [191]
Plumbago zeylanica L China Leaves [192]
Glycyrrhiza aspera Iran n/a [193]
Juglans regia Iran n/a [193]
Ligustrum vulgare Iran n/a [193]
Thymus kotschyanus Iran n/a [193]
Trachyspermum copticum Iran n/a [193]
Xanthium brasilicum Iran n/a [193]
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Continent and Species Parts Used Reference
Bacopa monniera [194]
Carthamus tinctorous L.( Asteraceae) Khorasan Flowers [195]
Satureja hortensis L.( Lamiaceae) Mashhad-Khorasan Leaves [195]
Artemisia dracunculus L. (Asteraceae) Mashhad-Khorasan Leaves [195]
Citrus sinensis L (Rutaceae) North of Iran Peel of fruit [195]
Punica granatum L. (Punicaceae) Saveh- Markazi Peel of fruit [195]
Apium petroselinum L (Apiaceae) Neishabur-Khorasan Seeds [195]
Carum bulbocastanum Iran Fruit [196]
Carum carvi Iran Fruit [196]
Mentha longifolia Iran Aerial [196]
Saliva limbata Iran Aerial [196]
Saliva sclarea Iran Aerial [196]
Ziziphora clinopodioides Iran Aerial [196]
Glycyrrhiza glabra Iran Root [196]
Thymus caramanicus Iran Aerial [196]
Xanthium brasilicum Iran Aerial [196]
Trachyspermum copticum Iran Fruits [196]
Acacia nilotica (L.)) (Fabaceae) Pakistan Leaves, flowers [197]
Calotropis procera (Aiton)( Apocynaceae) Pakistan Leaves, flowers [197]
Adhatoda vasica Nees (Zygophyllaceae) Pakistan Whole plant [197]
Fagoniaar abica L(Acanthaceae Pakistan Whole plant [197]
Casuarina equisetifolia L. (Casuarinaceae) Pakistan fruits [197]
AUSTRALIA
Pistacia (Mastic, Kurdica, Mutica and Cabolica) Sydney gums [198]
Others
Allium sativum L USA Leaves [125]
Capsaicin Pepper fruits [126]
Vaccitnium macrocarpon, C Cranberry [129]
Prunus mume Japan Juice [199]
Table 1. Anti-H. pylori medicinal plants occurring in more than one country worldwide
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6.2. Honey as a control measure of H. Pylori infections
Honey has been used in folk-medicine in many countries since antiquity [137]. It is mentioned
for healing purposes in the Bible, the Koran, and the Torah. Research related to honey has
revealed the promising effects of honey as an alternative source of H. pylori treatment [138].
Its beneficial qualities have been endorsed to its antimicrobial, antioxidant, anti-inflammatory
properties added to its phytocomponents [139]. Documentations now exist with proven ability
of Honey to inhibit microbial growth, and honey has been successfully used on infections that
do not respond to standard antiseptic and antibiotic therapy [28, 137]. In addition, In New
Zealand and Saudi Arabia it was observed that concentrations of honey at approximating 20%
v/v can inhibit the growth of H. pylori in vitro, grounded with the fact that MedihoneyTM and
manuka honeys have in vivo activity against ulcers, infected wounds and burns are significant
findings which merits further and extensive investigations [138]. Honey obtained from
different floral sources and different geographical region seem to vary in their antimicrobial
potency due to inherent differences in their chemical composition which is greatly influenced
by the prevailing climatic conditions and soil characteristics in the different geographical areas
influencing the plants as well the type of honey composition produced by the foraging bees
[140, 141]. Undoubtedly, several factors like floral source used to collect nectar, seasonal and
environmental factors, as well as processing and storage conditions might influence the
chemical composition of honey [142].
Honey is becoming acceptable as a reputable and effective therapeutic agent by practitioners
of conventional medicine and by the general public [139] Honey can be used as an antiseptic
for wounds, burns and ulcers, improving the assimilation of calcium and magnesium and
decreasing acidity [29, 143]. Stimulation of inflammatory- cytokine production by monocytes
and hydrogen peroxide produced as a result of injury or infection is likely the mechanism by
which wounds are healed with the use of honey [137, 144]. Motivated by these findings,
scientist sought out to investigate the activities of honeys further. Previously, the activity of
honey has been reported to differ with types [145]. The presence of hydrogen peroxide, osmotic
effect of honey, its naturally low pH, phenolic acids, lysosomes and flavanoids in honey are
all thought to help inhibit bacterial growth when honey is applied to a wound. Its low content
of water facilitates wound healing by hygroscopic absorption of water molecules on wound
surfaces and by soothing of the wound [137]. Honey does not only contain sugars but also an
abundance of minerals, vitamins, enzymes and amino acids [6, 137].
Anti- H. pylori activities of honey have been investigated with various honey types in different
parts of the world. Honey with proven anti- H. pylori activity is listed on (Table 2). Different
variety of honeys (crude) and solvent extracted honey have been shown to possess potential
compounds with therapeutic activity which could be exploited further as lead molecules in
the treatment of H. pylori infections [24]. Chemical analysis of the chloroform extract of the
pure honey led to the identification of 24 volatile compounds belonging to known chemical
families present in honey. Astoundingly, thiophene and N-methyl-D3-aziridine were identi‐
fied as novel compounds [146].
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Honey type Country References
Goldcrest honey South Africa [146]
Pure honey South Africa [146]
Citrus blossom South Africa [146]
Goldcrest South Africa [146]
Black forest Germany [137]
Langnese Germany [137]
Langnese Natural Bee Honey Germany [137]
Blossom Bee Honey Switzerland [137]
Al-Shifa Natural Honey Iran [137]
Al-Nada Clove Honey Oman [137]
Al-Nada Chestnut Honey Oman [137]
Manuka honey Zealand, [137]
Capillano Australia [137]
Table 2. Honey with Anti-H. pylori activity worldwide.
6.3. Use of probiotics in the treatment and management of H. pylori infections
According to an expert consultation conducted by the Food and Agriculture Organization and
the World Health Organization, probiotics are "live microorganisms which when administered
in adequate amounts confer a health benefit to the host." The regular intake of probiotic
microorganisms has been demonstrated to prevent several disorders including diarrhea and
inflammatory bowel disease [147]. Other advantages of the use of probiotics include the
inhibition of enteric pathogens such as Salmonella, Shigella and Citrobacter, the decreasing of
the luminal pH through the production of lactic acid or through competition with gut
pathogens for host surface receptors [148]. The usefulness of probiotics on the eradication of
H. pylori remains controversial. It has been suggested that the use of probiotic might have a
positive impact on Helicobacter eradication. However, some studies have demonstrated that
there was no change while some have shown an increase in the eradication rate of the bacteria
from about 60% to 83% [21, 149]. In vivo models demonstrated that pre-treatment with a
probiotic can prevent H. pylori infection and/or that administration of probiotics markedly
reduced an existing infection [150]. Probiotics are often administered as supplemental
treatment for the eradication of H. pylori. In this regard, a meta-analysis of 14randomized
clinical trials was conducted by [151]. This study evaluated the role of supplemental probiotics
in H. pylori eradication therapy and showed that the cure rates for standard antibiotic treatment
when used alone and eradication co-therapy with probiotics, were 74.8% and 83.6%, respec‐
tively. The analysis further showed that the combined treatment, had not only increased the
eradication rate, but had also decreased the occurrence of adverse effects due to antibiotics,
like diarrhea. Several probiotics have been shown to have a beneficial effect on H. pylori
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infection [150, 151]. However, the exact mechanisms of action have not been clearly elucidated
yet [152].
It is believed that probiotics may play an important role in the eradication and possibly the
prevention of H. pylori infection and could serve as adjunctive treatment. Several probiotics
have been shown to have beneficial effects on the treatment and eradication of H. pylori the
majority of these probiotics known as the lactic acid-producing bacteria. Among these
Bifidobacterium is one of the favorite genera, particularly in studies focused on the prevention
of gastrointestinal infection and is often used in fermented dairy products or food supplements
[153]. Some studies have been done in vitro (in test tubes or petri dishes) showing bifidobac‐
terial activity against H. pylori. Examples include Bifidobacterium lactis which has been dem‐
onstrated to have an enhancing activity on the phagocytic capacity of polymorpho-nuclear
cells [154]. Bifidobacterium spp have been shown to have positive effects of H. pylori infections.
These are generally administered in dairy products such as yogurt and milk. Clinical trial
studies have shown that probiotics-containing yogurt can offer benefits to restore Bifidobacte‐
rium spp ⁄ E. coli ratio in children and suppress the H. pylori load with increment of serum IgA
but with reduction in IL-6 in H. pylori-infected children [155]. The Lactobacillus group
constitutes an important source of probiotics that have been demonstrated to have a positive
effect on H. pylori treatment. Strains with this ability include Lactobacillus acidophilus, L. casei,
L. johnsonii, L. salivarius some of which are used as dairy starters [156]. Most studies have shown
that lactobacilli or their cell-free cultures can inhibit or even kill H. pylori by preventing its
adhesion to mammalian epithelial cells and preventing interleukin-8 release [157].
Fungal organisms particularly some strains of yeast have been used as probiotic as well.The best studied
example is S. boulardii which is a live yeast that has been used extensively as a probiotic and
often marketed as a dietary supplement [158]. It is a non-pathogenic yeast that has been
prescribed for prophylaxis and treatment of diarrheal diseases caused by bacteria (Reference).
Several clinical trials and experimental studies strongly suggest that Saccharomyces boulardii
has a biotherapeutic capacity for the prevention and treatment of several gastrointestinal
diseases including H. pylori infections [159]. S. boulardii mediates responses resembling the
protective effects of the normal healthy gut flora. In a study conducted in Turkey, S. boulardii
improved anti-H. pylori antibiotherapy-associated diarrhea, epigastric discomfort, and
treatment tolerability. However, S. boulardii had no significant effect on the rate of H. pylori
eradication in that study [160]. Importantly, S. boulardii has demonstrated clinical and exper‐
imental effectiveness in gastrointestinal diseases with a predominant inflammatory compo‐
nent, indicating that this probiotic might interfere with cellular signaling pathways common
in many inflammatory conditions [161]. In another study by Cremonini probiotic supplemen‐
tation significantly lowered the incidence of diarrhea and taste disturbance during H. pylori
eradication compared to the placebo group.
Generally, probiotics can be administered as single microbial species. However, in some cases
a combination of several types of probiotic species might yield a much more satisfactory result.
In a study by Dylag and colleagues, the combination of Lactobacillus, Bifidobacterium, Saccha‐
romyces boulardi and the treatment with Escherichia coli Nissle were found to be beneficial in
inducing and maintaining remission of disease activity of gut inflammation and moderately
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severe ulcerative colitis [162]. Preparations containing certain Lactobacillus, Bifidobacterium
strains or Saccaromyces boulardii could enhance by 5-10% the rate of successful eradication
of H. pylori and reduce the incidence and severity of the side effects [163]. Instead of considering
the probiotics alone, they have been considered in some studies as a safe adjuvant when added
to triple eradication therapy against the symptoms induced by the major gastric pathogen,
Helicobacter pylori.
Several mechanisms by which probiotic bacteria inhibit H. pylori have been proposed and
include immunological mechanisms, antimicrobial substances, competition for adhesion, and
the production of mucosal barrier [164]. Proposed mechanisms underlying the beneficial
interaction between probiotics and H. pylori, and the modulation of the colonization of the
gastric mucosa by this pathogen, include the production of lactic acid with H. pylori inhibition
because of decreasing gastric pH; the direct killing of H. pylori through secreted metabolites
with antimicrobial properties, including bacteriocins, autolysins, and organic acids; the
interference with H. pylori adhesion to epithelial cells, both through the secretion of antimi‐
crobial molecules and through direct competition for adhesion; and the ability to reduce H.
pylori-induced gastritis through the stabilization of the mucosal barrier, the secretion of
mucins, and the modulation of the host immune response to the infection [149]. Infection by
H. pylori, often induce and inflammatory response which in turn exacerbate the disease
through the increase production of inflammatory cytokines such as IL8 and TNF alpha. The
subsequent inflammatory processes as well as the bacterial infection generally persist for
decades resulting in mucosal damage, gastritis, and finally gastric neoplasm further potenti‐
ated by the failure of macrophages to eliminate H. pylori [165, 166]. One of the mechanisms by
which, probiotics reduce H. pylori infections is through the production of conjugated linoleic
acids. Conjugated linoleic acids (CLA) produced by Lactobacillus acidophilus for example was
reported to decrease the activation of nuclear factor-kappa B. In fact strains of probiotic bacteria
are known to convert linoleic acid to conjugated linoleic acid which has an immunomodulatory
activity [167]. A study conducted by Hwang and colleagues showed that conjugated linoleic
acid decreased the expressions of IL-8mRNA/protein as well as that of TNF-a mRNA [168].
This in turn, reduces the inflammation and therefore increases the cure rate of H. pylori
infection. Some probiotics such as L. acidophilus induce a Th1-polarizing response character‐
ized by high expression of interferon beta (IFN-β) and interleukin 12 (IL-12) [169]. This anti-
inflammatory effect is contrary to the inflammatory response induced by H. pylori and
therefore might reduce the effect of the infection on the host and increase the eradication of
the pathogen although H. pylori contain a pathogenic feature known as vac A which can block
the effect of the probiotic [170]. Studies by Yang and colleagues showed that higher doses of
L. acidophilus pre-treatment reduced H. pylori-induced inflammation through the inactivation
of the Smad7 and NFκB pathways by reversing the effect of H. pylori infection which often
induces Smad7, NFκB, IL-8, and TNF-a production [171].
Helicobacter pylori treatment has evolved tremendously over the past decade. The use of
different antibiotics has resulted to antibiotic resistance which has led to the adaptation of new
ways of controlling the organism. The use of medicinal plants has proven its worth. However,
much still need to be done, while very few clinical trials have been conducted over the last
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decade. Clinical trials for the use of medicinal plants for the control of H. pylori infections are
still awaited. The application of probiotics remains controversial although the tendency would
be that these organisms are helpful in increasing the eradication rate as well as the reduction
of the side effects of the infection.
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